Status:
NOT_YET_RECRUITING
Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer
Lead Sponsor:
Rabin Medical Center
Collaborating Sponsors:
MSD Pharmaceuticals LLC
Conditions:
NSCLC (Advanced Non-small Cell Lung Cancer)
NSCLC Stage IV Without EGFR/ALK Mutation
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study includes patients with advanced non-small cell lung cancer (NSCLC) - either unresectable stage III or stage IV adenocarcinoma without actionable driver mutations - who are treated with pemb...
Eligibility Criteria
Inclusion
- Histologically confirmed diagnosis of NSCLC adenocarcinoma stage IV or unresectable stage III.
- Have measurable disease based on RECIST 1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- Adequate organ function.
Exclusion
- Aberration in one or more of molecular drivers.
- Has received prior systemic anti-cancer therapy prior to allocation.
- Known active CNS metastases and/or carcinomatous meningitis.
- Known additional malignancy.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2028
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06951399
Start Date
September 1 2025
End Date
April 30 2028
Last Update
July 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Davidoff Comprehensive Cancer Center, Rabin Medical Center
Petah Tikva, Israel, 4941492